lt3001 drug product
Acute Ischemic Stroke
Shanghai Pharmaceuticals Holding Co., LtdPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 65/ 100
Competitive context
210 Active assets in the Acute Ischemic Stroke cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ticagrelor Sichuan Provincial People's Hospital | Phase 4 | BBB |
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Stanford University | Phase 4 | BBB |
Compound Edaravone Nanfang Hospital, Southern Medical University | Phase 4 | BBB |
Tenecteplase Hackensack Meridian Health | Phase 4 | BBB |
3-N-BUTYLPHTHALIDE Nanfang Hospital, Southern Medical University | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →